
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is attractive fundamentally because its biomarker-driven psychiatry strategy can enrich trials for patients most likely to respond, which should improve clinical success rates and strengthen eventual labeling across ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300. The biggest near-term driver is ALTO-207, where the PACE program now spans three trials, including a parallel Phase 3 adjunctive study and a planned monotherapy study, while independent PRIME-PRAXOL data validated pramipexole’s antidepressant signal and the ondansetron component addresses nausea. Financially, the July financing lifted pro forma cash to roughly $338 million, supporting planned operations through 2030 and giving the company time to advance multiple catalysts without near-term balance-sheet pressure.
Bears say
Alto Neuroscience is a clinical-stage biotech with promising but still unproven assets, and its dependence on biomarker-guided psychiatry leaves execution highly vulnerable to clinical readouts, regulatory outcomes, and safety signals. The pramipexole dataset from June supports the mechanism, but nausea in roughly 60% of treated participants highlights a meaningful tolerability issue that ALTO-207 is intended to address, underscoring that efficacy alone may not translate into a commercially viable profile. Financially, operating expenses rose to $29.1M from $18.7M, with R&D up 69% to $22.1M, and despite $244.2M in cash as of June 30, 2026 and about $338M pro forma after the July 2026 offering, the company is still expected to need additional funding and faces dilution risk if capital markets tighten.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares